GSK cuts prices for poor countries; FDA approves first new gout drug in 40 years;

> GlaxoSmithKline CEO Andrew Witty announced plans to slash drug prices in poor countries; he wants drugmakers and other patent-holders hand over IP on neglected tropical diseases to help jump-start development of remedies for those conditions. FiercePharma

> Breaking a therapeutic drought that has stretched over more than four decades, Takeda says it has won the FDA's approval of its new gout drug Uloric. FierceBiotech

> Officials at Dallas-based Parkland Memorial Hospital just fessed up that a system believed to be carrying names, birth dates and Social Security numbers of 9,300 employees has been stolen. FierceHealthIT

> A new international study shows that artificial light might increase a man's risk of developing prostate cancer. Article

And Finally... Here's one way to ensure that thieves don't get away with their crimes. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.